Page contentsPage contentsKey factsDecisionKey facts Active Substance belantamab mafodotin Therapeutic area Oncology Decision number P/0347/2019 PIP number EMEA-002468-PIP04-18 Pharmaceutical form(s) Powder for concentrate for solution for infusion Condition(s) / indication(s) Treatment of Multiple Myeloma Route(s) of administration Intravenous use Contact for public enquiries GlaxoSmithKline Trading Services LimitedTel. +1 438-899-8201E-mail: eu.paediatric-plans@gsk.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 11/09/2020DecisionP/0347/2019: EMA decision of 11 September 2019 on the granting of a product specific waiver for belantamab mafodotin (EMEA-002468-PIP04-19)AdoptedReference Number: EMA/439999/2019 English (EN) (166.25 KB - PDF)First published: 25/03/2020ViewShare this page